ctDNA as a marker for immunotherapy in advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or locally advanced colorectal cancer with a specific genetic type called dMMR/MSI-H.
- You are expected to receive or are already receiving a type of immunotherapy called immune checkpoint inhibitors.
- Your overall health is good (ECOG score 0 or 1), meaning you are fully active or slightly restricted but can still do light work.
- Your life expectancy is at least 12 weeks (about 3 months).
- You do not have any other active cancer that is not cured.
- You do not have a serious ongoing illness (like uncontrolled diabetes, heart disease, etc.) that would make it hard to complete the study.
- You do not have an autoimmune disease that would prevent you from safely receiving PD-1 immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This trial is for people with colorectal cancer whose ctDNA blood test is still positive after surgery and chemotherapy. It tests two immunotherapy drugs (cemiplimab alone or with fianlimab) to see if they can eliminate the remaining cancer cells and prevent the cancer from coming back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.